A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
NCT ID: NCT04058353
Last Updated: 2021-07-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
271 participants
INTERVENTIONAL
2019-08-28
2020-06-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT04058366
A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
NCT04105972
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03525548
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT03525574
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
NCT04353817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control: IVA or TEZ/IVA
Following an IVA or TEZ/IVA run-in period of 4 weeks, participants either received IVA 150 milligrams (mg) every 12 hours (q12h) or TEZ 100 mg once daily (qd)/IVA 150 mg q12h in the treatment period for 8 weeks.
IVA
Mono-tablet for oral administration.
TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration.
TC: ELX/TEZ/IVA
Following an IVA or TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 8 weeks.
ELX/TEZ/IVA
FDC tablet for oral administration.
IVA
Mono-tablet for oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELX/TEZ/IVA
FDC tablet for oral administration.
IVA
Mono-tablet for oral administration.
TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height
Exclusion Criteria
* Lung infection with organisms associated with a more rapid decline in pulmonary status
* Solid organ or hematological transplantation
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Banner University of Arizona Medical Center
Tucson, Arizona, United States
Miller Children's Hospital / Long Beach Memorial
Long Beach, California, United States
Stanford University
Palo Alto, California, United States
University of California Davis Medical Center
Sacramento, California, United States
University of California San Francisco, Lung Transplant Program
San Francisco, California, United States
National Jewish Health
Denver, Colorado, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Central Florida Pulmonary Group, PA
Orlando, Florida, United States
Indiana University
Indianapolis, Indiana, United States
The University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
University of Kentucky
Lexington, Kentucky, United States
Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center
Boston, Massachusetts, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Michigan Medicine
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Washington University School of Medicine / St. Louis Children's Hospital
St Louis, Missouri, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Northwell Health- Long Island Jewish Medical Center
New Hyde Park, New York, United States
Mount Sinai Beth Israel
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
University of North Carolina Hospitals
Chapel Hill, North Carolina, United States
UC Health Holmes
Cincinnati, Ohio, United States
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center
Toledo, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Oregon Health & Science University
Portland, Oregon, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
Dell Children's Medical Group
Austin, Texas, United States
The University of Texas Southwestern Medical Center
Dallas, Texas, United States
Texas Children's Hospital
Houston, Texas, United States
University of Utah / Primary Children's Medical Center
Salt Lake City, Utah, United States
University of Washington Medical Center
Seattle, Washington, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
The Prince Charles Hospital
Chermside, , Australia
Alfred Hospital
Melbourne, VIC, , Australia
Perth Children's Hospital
Nedlands, , Australia
The Royal Children's Hospital
Parkville, VIC, , Australia
Mater Adult Hospital
South Brisbane, , Australia
Queensland Children's Hospital
South Brisbane, , Australia
Westmead Hospital
Westmead, , Australia
Cliniques Universitaires de Bruxelles Hopital Erasme
Brussels, , Belgium
Universitair Ziekenhuis Brussel - Campus Jette
Brussels, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, , Belgium
Stollery Children's Hospital
Edmonton, , Canada
McGill University Health Center
Québec, , Canada
St. Michael's Hospital
Toronto, , Canada
St. Paul's Hospital
Vancouver, , Canada
Juliane Marie Center, Rigshospitalet
Copenhagen, , Denmark
Centre Hospitalier Lyon Sud
Benite Cedex, , France
Groupe Hospitaler Pellegrin, CHU De Bordeaux
Bordeaux, , France
CHRU de Lille - Hopital Albert Calmette
Lille, , France
CHU Marseille - Hopital Nord
Marseille, , France
CHU de Montpellier - Hopital Arnaud de Villeneuve
Montpellier, , France
Hopital Cochin
Paris, , France
Hopital Necker, Enfants Malades
Paris, , France
Hopital Pontchaillou CHU de Rennes
Rennes, , France
Charite Paediatric Pulmonology Department
Berlin, , Germany
Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital
Erlangen, , Germany
Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen
Essen, , Germany
Justus-Liebig-Universitaet Gießen Zentrum fur Kinderheilkunde und Jugendmedizin
Giessen, , Germany
Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie
Halle, , Germany
Pneumologisches Studienzentrum Muenchen-West
München, , Germany
University Hospital Wuerzburg
Würzburg, , Germany
Cork University Hospital
Cork, , Ireland
Beaumont Hospital
Dublin, , Ireland
St. Vincent's University Hospital
Dublin, , Ireland
University Hospital Limerick (Adults)
Limerick, , Israel
Azienda Ospedaliero Universitaria Ospedale Riuniti
Ancona, , Italy
IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico
Genova, , Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, , Italy
Malattie Apparato Respiratorio 2 - Fibrosi Cistica
Orbassano, , Italy
Ospedale Pediatrico Bambino Gesu
Rome, , Italy
Azienda Ospedaliera di Verona-Ospedale Civile Maggiore
Verona, , Italy
University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis
Heidelberglaan, , Netherlands
UMC St. Radboud
Nijmegen, , Netherlands
HagaZiekenhuis van den Haag
The Hague, , Netherlands
Hospital Universitari Vall d´Hebron Servicio de Broncoscopia
Barcelona, , Spain
Hospital Virgen de la Arrixaca
Murcia, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Universitario y Politecnico La Fe
Valencia, , Spain
Papworth Hospital NHS Foundation Trust, Papworth Everard
Cambridge, , United Kingdom
Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital
Exeter, , United Kingdom
Clinical Research Facility, Queen Elizabeth University Hospital
Glasgow, , United Kingdom
St. James University Hospital
Leeds, , United Kingdom
Liverpool Heart and Chest Hospital
Liverpool, , United Kingdom
Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
London, , United Kingdom
Wythenshawe Hospital
Manchester, , United Kingdom
Southampton General Hospital
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Barry PJ, Mall MA, Alvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-002835-76
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
VX18-445-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.